Ces Urol 2025, 29(1):17-21 | DOI: 10.48095/cccu2025003

Hyperprolactinemia and erectile dysfunction

Marek Broul1–3, Aneta Hujová3, Lucie Radovnická4, Alberto Malucelli5, Eva Jozífková6
1 Sexuologické oddělení, Krajská zdravotní, a.s. – Masarykova nemocnice v Ústí nad Labem, o.z.
2 Urologické oddělení, Krajská zdravotní, a.s. – Nemocnice Litoměřice, o.z.
3 Katedra ošetřovatelství, Fakulta zdravotnických studií UJEP v Ústí nad Labem
4 Interní oddělení, Krajská zdravotní, a.s. – Masarykova nemocnice v Ústí nad Labem, o.z.
5 Neurochirurgická klinika FZS UJEP a Krajská zdravotní, a.s. – Masarykova nemocnice v Ústí nad Labem, o.z.
6 Katedra bio­logie, Přírodovědecká fakulta UJEP v Ústí nad Labem

In addition to hypogonadism, other endocrine dis­eases are associated with male sexual dysfunction. In this article, we review the role of the pituitary hormone prolactin in male sexual dysfunction, and in particular in erectile dysfunction. Erectile dysfunction is common in men with hyperprolactinemia. Treatment of this primary cause may affect normal erectile function. In our patient cohort, after treatment of hyperprolactinemia (medical and surgical), prolactin levels normalized in all treated patients. Erectile dysfunction in all men was treated with some type of phosphodiesterase 5 inhibitor - i.e. sildenafil, tadalafil, vardenafil, avanafil. After the treatment of the primary cause of erectile dysfunction, there was then also an improvement in IIEF-5 (International Index of Erectile Function) score and therefore erectile function in all our patients.

Keywords: erectile dysfunction, prolactin, pituitary adenoma, IIEF-5 questionnaire, hyperprolactinemia

Received: November 22, 2024; Revised: January 25, 2025; Accepted: January 27, 2025; Prepublished online: January 27, 2025; Published: March 25, 2025 

Open full article

References

  1. Miller JB, Howards SS, Mcleod RM. Serum prolactin in organic and psychogenic impotence. J Urol 1980; 123(6): 862-864. doi: 10.1016/s0022-5347(17)56166-2. Go to original source... Go to PubMed...
  2. Perryman RL, Thorner MO. The effects of hyperprolactinemia on sexual and reproductive function in men. J Androl 1981; 5: 233-242. Go to original source...
  3. Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction. Rev Urol 2000; 2(1): 39-42.
  4. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin - a hormone of the anterior pituitary. Am J Physiol - Legacy Content 1933: 191-216. doi: 10.1152/ajplegacy.1933.105.1.191. Go to original source...
  5. Kelly MA, Rubinstein M, Asa SL et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997; 19(1): 103-113. doi: 10.1016/s0896-6273(00)80351-7. Go to original source... Go to PubMed...
  6. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2025 [online]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507829/.
  7. Ježková J, Brutvan T. Adenomy hypofýzy z pohledu internisty. Vnitr Lek 2024; 70(1): 7-12. doi: 10.36290/vnl.2024.001. Go to original source...
  8. Kršek M. Hyperprolaktinémie a prolaktinomy. Interní Med 2002; 4(11): 530-536.
  9. Faglia G. Prolactinomas and hyperprolactinemic syndrome. In: DeGroot LJ, Jameson JL (eds.) Endocrinology (4th ed). Philadelphia: Saunders 2000: 329-342.
  10. Johnson 3rd AR, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol 1992; 147(6): 1542-1543. doi: 10.1016/s0022-5347(17) 37620-6. Go to original source... Go to PubMed...
  11. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158(5): 1764-1767. doi: 10.1016/s0022-5347(01)64123-5. Go to original source... Go to PubMed...
  12. Slag MF, Morley JE, Elson MK et al. Impotence in medical clinic outpatients. Jama 1983; 249(13): 1736-1740. Go to original source...
  13. Broul M, Kučerová P, Jozífková E et al. Treatment of thyroid disorder supported by 5-phosphodiesterase inhibitors improved erectile dysfunction in patients with hypo-and hyperthyroidism. Neuro Endocrinol Lett 2024; 45(3): 180-187.
  14. Carter JN, Tyson JE, Tolis G et al. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978; 299(16): 847-852. doi: 10.1056/NEJM197810192991602. Go to original source... Go to PubMed...
  15. Tolis G. Prolactin: physiology and pathology. Hosp Pract 1980; 15(2): 85-95. doi: 10.1080/21548331.1980.11946556. Go to original source... Go to PubMed...
  16. Veselský Z. Vztah prolaktinu a testosteronu u mužů se sexuální dysfunkcí. Urolog. pro Praxi 2005; 6: 264-268.
  17. Dombrowski RC, Romeo JH, Aron DC. Verapamil-induced hyperprolactememia complicated by a pituitary incidentaloma. Ann Pharmacother 1995; 29(10): 999-1001. doi: 10.1177/106002809502901009. Go to original source... Go to PubMed...
  18. Nickel JC, Morales A, Condra M et al. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984; 132(1): 40-43. doi: 10.1016/s0022-5347(17)49454-7. Go to original source... Go to PubMed...
  19. Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction. Rev Urol 2000; 2(1): 39-42.
  20. Buvat, J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 2003; 15(5): 373-377. doi: 10.1038/sj.ijir.3901043. Go to original source... Go to PubMed...

Return to the content



Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.


Odejít Vstoupit